Acute postprandial effect of yacon syrup ingestion on appetite: A double blind randomized crossover clinical trial.

Yacon syrup is a rich source of fructooligosaccharides (FOS); however, its diet supplementation effect on subjective sensation and appetite biomarkers in human is still unknown. This study aimed to evaluate the acute postprandial effect of yacon syrup ingestion on appetite. The double-blind crossover clinical trial was carried out with 40 adult women: 20 eutrophic and 20 obese grade I. On each day, the first blood collection was performed after a 12-h fast. Then, the volunteers ingested either intervention A (breakfast + 40 g of placebo) or intervention B (breakfast + 40 g of yacon syrup, containing 14 g of FOS). New aliquots of blood were collected at 45, 60, 90, 120, and 180 min. Appetite was assessed by estimating ghrelin and glucagon-like peptide-1 (GLP-1) levels and by assessing subjective appetite sensation. Analysis was performed using two-way ANOVA, followed by Bonferroni's multiple comparison test. No effect of yacon syrup was observed on postprandial ghrelin and GLP-1 levels at all times evaluated. Similar observations were made after stratifying the analysis by BMI (body mass index) (eutrophic and obese). The effect of yacon syrup on postprandial subjective sensations of hunger, satiety, fullness, and desire to eat was not evident in the total group of women evaluated and even after BMI stratification. We concluded that yacon syrup had no effect on postprandial ghrelin and GLP-1 levels and on the subjective appetite sensation in young adult women.

Dietary Inflammatory Index and clinical course of multiple sclerosis.

OBJECTIVES: This study aims at analyzing the association between the Dietary Inflammatory Index (DII) and the clinical condition of multiple sclerosis (MS) patients. METHODS: It is a quantitative, cross-sectional analytical study that included 137 MS patients assisted at a reference center for MS treatment in the Brazilian northeast. Data was collated through a structured questionnaire and medical records consultation, also involving demographic, clinical, and nutritional variables. Clinical variables included the MS type, diagnosis and follow-up start dates, investigation of recent urinary tract symptoms, use of immunomodulatory, vitamin D supplementation, number of recent pulse therapies, relapse rate in the last 2 years, muscular strength assessment (MRC), disability degree (EDSS), and a gadolinium-enhanced magnetic resonance imaging (MRI) scan in the central white matter (CWM). The DII was calculated according to the Shivappa et al. methodology. RESULTS: There was no difference in any of the variables according to the DII (p > 0.05). CONCLUSIONS: The Dietary Inflammatory Index did not affect the clinical condition of individuals with multiple sclerosis.